Across TCGA pan-cancer cohorts, FAM189A2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FAM189A2 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM189A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM189A2 expression acts as an unfavorable survival marker.
UCEC and LIHC are the cancer types where FAM189A2 Mutation most reproducibly stratifies survival.